EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RIPK2 induces docetaxel resistance in prostate cancer through the NF-κB/P-gp signaling pathway

Shaoqiang Xing, Zhaoliang Xu, Sheng Zeng, Minghao Yue, Wenzhou Xing, Qian Liu iD

PLOS One · 2026

DOI: 10.1371/journal.pone.0341445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Shaoqiang Xing und 5 weiteren Autor:innen. Beteiligte Einrichtung: The First Central Clinical School, Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Docetaxel, Receptor-Interacting Protein Serine-Threonine Kinase 2, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tianjin Key Medical Discipline(Specialty) Construction Project..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemoresistance is a reason for treatment failure in prostate cancer. Receptor-interacting protein kinase 2 (RIPK2) has been shown to play a role in drug resistance in various cancers; however, its role and the underlying mechanism of chemoresistance in prostate cancer are unclear. We analyzed data from The Cancer Genome Atlas for RIPK2 expression in prostate cancer and its association with clinicopathological features. We also elucidated the role and mechanism of action of RIPK2 in prostate cancer cell resistance to docetaxel (DTX). The results showed that RIPK2 expression was upregulated in prostate cancer tissues and was associated with poor pathological grading. RIPK2 was also upregulated in 22RV1/DTX, C4-2/DTX, PC-3/DTX, and DU145/DTX cell lines and involved in DTX resistance. Mechanistic experiments revealed that RIPK2 was involved in DTX resistance by upregulating P-glycoprotein (P-gp) expression through the activation of the NF-κB signaling pathway. Xenograft tumor experiments confirmed that inhibition of RIPK2 or P-gp enhanced the efficacy of DTX in suppressing PC-3/DTX growth. Taken together, these results suggest that RIPK2 mediates DTX resistance in prostate cancer cells through the NF-κB/P-gp signaling pathway. RIPK2 and its downstream signaling molecules are potential targets for the treatment of chemoresistant prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsDocetaxelReceptor-Interacting Protein Serine-Threonine Kinase 2Drug Resistance, NeoplasmNF-kappa BATP Binding Cassette Transporter, Subfamily B, Member 1Antineoplastic AgentsMaleHumansSignal TransductionAnimalsCell Line, TumorMiceGene Expression Regulation, NeoplasticTaxoidsMice, NudeXenograft Model Antitumor Assays

Substanzen

DocetaxelReceptor-Interacting Protein Serine-Threonine Kinase 2NF-kappa BRIPK2 protein, humanATP Binding Cassette Transporter, Subfamily B, Member 1Antineoplastic AgentsTaxoids

Autor:innen und Institutionen

  • The First Central Clinical School, Tianjin Medical University, Tianjin, China.
  • Department of Urology, Tianjin First Central Hospital, Tianjin, China.

ORCID-Profile: Qian Liu

Förderung

  • Tianjin Key Medical Discipline(Specialty) Construction Project.

Zitieren

APA

Xing, S., Xu, Z., Zeng, S., Yue, M., Xing, W., & Liu, Q. (2026). RIPK2 induces docetaxel resistance in prostate cancer through the NF-κB/P-gp signaling pathway. PLOS One. https://doi.org/10.1371/journal.pone.0341445

Vancouver

Xing S, Xu Z, Zeng S, Yue M, Xing W, Liu Q. RIPK2 induces docetaxel resistance in prostate cancer through the NF-κB/P-gp signaling pathway. PLOS One. 2026. doi:10.1371/journal.pone.0341445

BibTeX
@article{Xing2026,
  author = {Xing, Shaoqiang and Xu, Zhaoliang and Zeng, Sheng and Yue, Minghao and Xing, Wenzhou and Liu, Qian},
  title = {RIPK2 induces docetaxel resistance in prostate cancer through the NF-κB/P-gp signaling pathway},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0341445}
}
Kostenlos starten →